December 2024 – Page 17

Empowering Patients: The Key to Faster, More Impactful Research

6 months ago talkbio0Tagged Clinical Research, Empowerment, Engaged to be married, Health care facility, outcomes, Patient-Centered Care, Precision Medicine

Patient-centered care, Patient engagement, Personalized medicine, Clinical research, Healthcare outcomes, Patient empowerment

GSK Extends Shingrix Collaboration with Zhifei in China, Explores RSV Vaccine Partnership

6 months ago talkbio0Tagged Arexvy, China, Collaboration, Respiratory syncytial virus, Shingrix, SmithKline Beecham, Vaccines, Zhifei

GSK, Zhifei, Shingrix, RSV vaccine, Arexvy, China, vaccine collaboration

Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)

6 months ago talkbio0Tagged anti-C5, Avoidance, Blood Transfusion, Effectiveness, Fabhalta, Hemoglobin improvement, Iptacopan, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Safety, Switching therapies

Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance

Novo Holdings Receives Unconditional EU Approval for $16.5 Billion Acquisition of Catalent

6 months ago talkbio0Tagged Acquisition, Approved, Catalent, Commission, EU, European (ethnic group), Holdings, Pharmaceutical Services

Novo Holdings, Catalent, European Commission, Acquisition, EU Approval, Pharmaceutical Services

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

6 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile

Protara Therapeutics Sees Significant Stock Surge Following Positive Phase 2 Trial Results for TARA-002 in Bladder Cancer

6 months ago talkbio0Tagged Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant neoplasm of urinary bladder, Non-Muscle Invasive Bladder Neoplasms, Phase 2 trial, Protara Therapeutics, safety profile

Protara Therapeutics, TARA-002, bladder cancer, NMIBC, Phase 2 trial, complete response rate, safety profile

Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch

6 months ago talkbio0Tagged cancer medicine, Cyclacel, development aspects, Financial cost, Financial Stress, Nasdaq, Risk, strategic alternatives

Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development

Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns

6 months ago talkbio0Tagged Acquisitions, Administration occupational activities, Biopharma, Independence, Inflation, mergers, Policy, Transplant Registry Unified Management Program, United States Food and Drug Administration, Vaccines

Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

6 months ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy

AstraZeneca Appoints Iskra Reic as New International Operations Lead Following Investigation into China Executive

6 months ago talkbio0Tagged AstraZeneca, China, Evaluation, international operations lead, Iskra Reic, Leon Wang

AstraZeneca, Iskra Reic, Leon Wang, China investigation, international operations lead